摘要
目的观察重组人生长激素(rhGH)联合亮丙瑞林对中枢性性早熟(CPP)女童子宫卵巢超声指标、性激素和血清骨形成标志物水平的影响.方法选取2021年2月-2024年1月于都县人民医院收治的104例CPP女性患儿,随机分为A组(n=52)与B组(n=52).B组给予亮丙瑞林治疗,A组在B组基础上给予rhGH治疗.对比两组临床疗效、治疗前后子宫卵巢超声指标(子宫容积、卵巢容积)、血清性激素[黄体生成素(LH)、雌二醇(E2)]和骨形成标志物[氨基端前C-型利钠肽(NT-proCNP)、骨碱性磷酸酶(BAP)、骨钙素(OC)、胰岛素样生长因子1(IGF-1)]水平、不良反应发生率.结果A组治疗总有效率为92.31%,高于B组的76.92%(P<0.05).治疗后A组子宫容积、卵巢容积低于B组(P<0.05).治疗后A组血清LH、E2、NT-proCNP、BAP、OC、IGF-1水平低于B组(P<0.05).两组不良反应发生率对比,差异不显著(P>0.05).结论rhGH联合亮丙瑞林治疗CPP女性患儿,可提高临床疗效,缩小子宫卵巢容积,减少性激素分泌,降低骨形成标志物水平,安全性高.
Objective To observe the effects of recombinant human growth hormone(rhGH)combined with leuprelin on the levels of uterine and ovarian ultrasound indexes,sex hormones and serum markers of bone formation in girls with central precocious puberty(CPP).Methods 104 female children with CPP in Yudu County People's Hospital from February 2021 to January 2024 were selected and randomly divided into Group A(n=52)and Group B(n=52)using a random number table method.Group B received treatment with leuprorelin,while Group A received rhGH treatment on the basis of Group B.Compare the clinical efficacy,uterine and ovarian ultrasound indicators(uterine volume,ovarian volume),serum sex hormones[luteinizing hormone(LH),estradiol(E2)],bone formation markers[N-Terminal Pro-C-Type Natriuretic Peptide(NT-proCNP),bone alkaline phosphatase(BAP),osteocalcin(OC),insulin-like growth factor-1(IGF-1)]levels,and incidence of adverse reactions between two groups before and after treatment.Results The total effective rate of treatment in Group A was 92.31%,which was higher than that in Group B at 76.92%(P<0.05).After treatment,the uterine and ovarian volumes in Group A were lower than those in Group B(P<0.05).After treatment,the serum LH,E2,NT-proCNP,BAP,OC,and IGF-1 levels in Group A were lower than those in Group B(P<0.05).Comparison of incidence rates of adverse reactions between two groups(P>0.05).Conclusion rhGH combined with leuprelin in the treatment of female children with CPP can improve clinical efficacy,reduce utero-ovarian volume,reduce sex hormone secretion,and reduce the level of bone formation markers,with high safety.
作者
谢丽雯
温琳玲
Xie Liwen;Wen Linling(Yudu County People's Hospital,Ganzhou,Jiangxi 342300,China)
出处
《首都食品与医药》
2024年第18期67-69,共3页
Capital Food Medicine
关键词
重组人生长激素
亮丙瑞林
中枢性性早熟
性激素
骨形成标志物
Recombinant human growth hormone
Levoprorelin
Central precocious puberty
Sex hormone
Bone formation marker
